Introduction:

Acute myeloid leukemia is a clonal disease, recognized as one of the most heterogeneous malignant hemopathy in which certain clinical, immunological, cytogenetic and molecular biomarkers influence the response of patients to treatment.

Objective:

Describe the prognostic influence of immunological, cytogenetic and molecular biomarkers on the therapeutic response in adult patients under 60 years of age with acute myeloid leukemia.

Methods:

An exhaustive review was conducted about the topic in the databases as Pubmed, Scielo, ScienceDirect, Medline and Scholar Google, for which papers mainly published in the last five years were used as reference.

Analysis and synthesis of the information:

The immunological, cytogenetic and molecular heterogeneity of adult patients under 60 years of age with acute myeloid leukemia is related to the variability in the response to treatment that patients have and affects their overall and disease-free survival.

Conclusions:

Based on the immunological, cytogenetic and molecular characteristics, it is possible to establish the prognosis of patients with acute myeloid leukemia, which allows selecting the appropriate therapy to reduce complications, relapses as much as possible and increase overall survival.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )